Semnur Pharmaceuticals, Inc.
SMNR
$0.84
$0.045.01%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.31M | 5.44M | 151.45M | 497.00K | 478.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.58M | 6.16M | 152.59M | 999.00K | 665.00K |
| Operating Income | -4.58M | -6.16M | -152.59M | -999.00K | -665.00K |
| Income Before Tax | -4.58M | -6.16M | -152.59M | -999.00K | -665.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.58M | -6.16M | -152.59M | -999.00K | -665.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.58M | -6.16M | -152.59M | -999.00K | -665.00K |
| EBIT | -4.58M | -6.16M | -152.59M | -999.00K | -665.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.03 | -0.76 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.47 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.03 | -0.76 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.47 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 230.21M | 217.43M | 201.69M | 160.00M | 200.00M |
| Average Diluted Shares Outstanding | 230.21M | 217.43M | 201.69M | 160.00M | 200.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |